Allergy
Therapeutics
plc
("Allergy Therapeutics" or the "Company")
PDMR
Dealings
Issue of 687,500,000
Warrants
15
January 2025 - Allergy Therapeutics
plc (AIM: AGY), the fully integrated commercial biotechnology
company specialising in allergy vaccines, today announces that,
further to the Company's announcements on 16 October 2024 and 27
December 2023, it has issued certificates in respect of 687,500,000
warrants to subscribe for new ordinary shares in the Company
("Warrants").
As previously announced, pursuant to
the terms of the £50 million loan facility under the facility
agreement dated 6 April 2023 with SkyGem Acquistion Limited (an
affiliate of ZQ Capital Management Limited) ("SkyGem") and Southern Fox Investments
Limited ("Southern Fox"),
as amended from time to time, ("the Amended Loan Facility") the Company
agreed to issue 25 Warrants for every £1 drawn under the Amended
Loan Facility at an exercise price of 4 pence per Warrant and
exercisable on or prior to 15 October 2030. The Company confirms
that is has now issued certificates in respect of 457,937,500
Warrants to SkyGem and 229,562,500 Warrants to Southern Fox in
accordance with the terms of the Amended Loan
Facility.
In addition to these Warrants, each
of Sky Gem and Southern Fox hold 16,666,666 Warrants with an
exercise price of 30 pence per Warrant and exercisable until 28
February 2028.
For further information, please
contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Geoff Nash /Giles Balleny/ Seamus
Fricker / Rory Sale
Nigel Birks - Life Science
Specialist Sales
Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for
editors:
About Allergy
Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. For more information, please see www.allergytherapeutics.com.
Notification and public
disclosure of transactions by Director/persons discharging
managerial responsibilities ("PDMR") and persons closely associated
with them ("PCA")
|
1
|
Details of the person
discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Southern
Fox Investments Limited
|
|
2
|
Reason for the
notification
|
|
|
a)
|
Position/status
|
Persons
closely associated Mr. Anthony Parker, Non-Executive Director of
Allergy Therapeutics Plc.
|
|
b)
|
Initial
notification/Amendment
|
Initial
notification.
|
|
3
|
Details of the issuer, UK
emission allowance market participant, auction platform or
auctioneer
|
|
a)
|
Name
|
Allergy
Therapeutics Plc
|
|
b)
|
LEI
|
213800PQ7AHK7KGVOE23
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
|
Warrant
Instrument
|
|
b)
|
Nature of
the transaction
|
Issue of
warrants representing subscription rights for ordinary shares of
£0.001 each.
|
|
c)
|
Price(s)
and volume(s)
|
Exercise
Price(s)
|
Volume(s)
|
|
£0.04 (4
pence) per warrant
|
229,562,500
|
|
|
|
d)
|
Aggregated
information
· - Aggregated volume
· - Price
|
n/a
|
|
e)
|
Date of the
transaction
|
14 January
2025
|
|
f)
|
Place of
the transaction
|
Outside a
trading venue.
|
|
1
|
Details of the person
discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
ZQ Capital
Management Limited
|
|
2
|
Reason for the
notification
|
|
|
a)
|
Position/status
|
Persons
closely associated Mr. Zheqing Shen, Non-Executive Director of
Allergy Therapeutics Plc.
|
|
b)
|
Initial
notification/Amendment
|
Initial
notification.
|
|
3
|
Details of the issuer, UK
emission allowance market participant, auction platform or
auctioneer
|
|
a)
|
Name
|
Allergy
Therapeutics Plc
|
|
b)
|
LEI
|
213800PQ7AHK7KGVOE23
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
|
Warrant
Instrument
|
|
b)
|
Nature of
the transaction
|
Issue of
warrants representing subscription rights for ordinary shares of
£0.001 each.
|
|
c)
|
Price(s)
and volume(s)
|
Exercise
Price(s)
|
Volume(s)
|
|
£0.04 (4
pence) per warrant
|
457,937,500
|
|
|
|
d)
|
Aggregated
information
· - Aggregated volume
· - Price
|
n/a
|
|
e)
|
Date of the
transaction
|
14 January
2025
|
|
f)
|
Place of
the transaction
|
Outside a
trading venue.
|